<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hemicrania continua
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hemicrania continua
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hemicrania continua
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ivan Garza, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd J Schwedt, MD, MSCI
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerry W Swanson, MD, MHPE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemicrania continua (HC) is a unilateral headache that is continuous in nature. HC belongs to the trigeminal autonomic cephalalgias (TACs), a group of idiopathic headache disorders characterized by unilateral headaches accompanied by ipsilateral cranial autonomic symptoms. Other TACs include cluster headache, paroxysmal hemicrania, and short-lasting unilateral neuralgiform headache attacks.
        </p>
        <p>
         Other types of chronic daily headache include chronic migraine, chronic tension-type headache, medication overuse headache, and new daily persistent headache and are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/3333.html" rel="external">
          "Chronic daily headache: Associated syndromes, evaluation, and management"
         </a>
         .)
        </p>
        <p>
         Other TACs are discussed elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3326.html" rel="external">
          "Cluster headache: Epidemiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3351.html" rel="external">
          "Cluster headache: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3334.html" rel="external">
          "Paroxysmal hemicrania: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3335.html" rel="external">
          "Paroxysmal hemicrania: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3336.html" rel="external">
          "Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3338.html" rel="external">
          "Short-lasting unilateral neuralgiform headache attacks: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H588294959">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The posterior hypothalamus, dorsal rostral pons, and trigeminal nociceptive pathways in the caudal brainstem play a role in the physiology of HC. A controlled positron emission tomography (PET) study of seven patients with HC showed significant activation of the contralateral posterior hypothalamus and ipsilateral rostral pons during baseline pain [
         <a href="#rid1">
          1
         </a>
         ]. This activation was blocked by administration of intramuscular
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         .
        </p>
        <p>
         It is hypothesized that the presence of cranial autonomic nervous system symptoms in HC is due, at least in part, to hypothalamic activation with secondary disinhibition of the trigeminal-autonomic reflex [
         <a href="#rid2">
          2
         </a>
         ]. A similar mechanism may be implicated in cluster headache and the short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) headache syndromes. The exact role of the dorsal rostral pons in HC is unclear, but this region is also activated in migraine and may play a role in the inhibition of nociceptive traffic along the trigeminovascular system.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term "hemicrania continua" was coined in 1984 when the first cases were described [
         <a href="#rid3">
          3
         </a>
         ]. The true frequency of HC in the general population is unknown as only about 1000 cases have been published in the literature [
         <a href="#rid4">
          4
         </a>
         ]. However, HC accounts for up to 2 percent of patients with headache presenting to headache specialty or neurology clinics, suggesting the disorder may be more prevalent than previously considered [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         HC tends to have onset in the fourth to sixth decades of life but with a range from the first to eighth decades [
         <a href="#rid6">
          6
         </a>
         ]. The estimated female to male ratio is 2:1 [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         As the name implies, HC is a unilateral headache that is continuous in nature, at least for the unremitting form. Additional common features of HC include cranial autonomic symptoms, a sense of restlessness or agitation during exacerbations, and responsiveness to
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Most patients with HC have unremitting pain, but up to 20 percent have pain-free periods that can last for one day to several months [
         <a href="#rid8">
          8
         </a>
         ]. Pain is most commonly located anteriorly in the orbit, frontal regions, and temporal regions, but pain in the occiput is not rare [
         <a href="#rid9">
          9
         </a>
         ]. Involvement of other regions of the head and neck has also been described. Although pain is continuous, it fluctuates in severity with superimposed attacks of more severe pain. Pain exacerbations last from minutes to several days [
         <a href="#rid10">
          10
         </a>
         ]. Pain intensity ranges from mild to severe, but the pain of HC is not as excruciatingly severe as the pain of cluster headache.
        </p>
        <p>
         During episodes of superimposed severe pain, there is usually evidence of cranial autonomic activation, although some patients with HC do not report cranial autonomic symptoms [
         <a href="#rid8">
          8,11
         </a>
         ]. The most common cranial autonomic features, in approximate order of frequency, are the following [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lacrimation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasal congestion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conjunctival injection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ptosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Forehead/facial flushing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rhinorrhea
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Forehead/facial sweating
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eyelid edema
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aural fullness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aural swelling
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Miosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mydriasis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Facial edema
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dripping sensation at the back of the throat
        </p>
        <p>
        </p>
        <p>
         Eye itching or a sense of ocular discomfort, as if there is something in the eye (termed the false foreign body sensation), is often reported by patients with HC [
         <a href="#rid8">
          8,9,12
         </a>
         ]. The autonomic features of HC are generally less prominent than those seen with the other trigeminal autonomic cephalalgias (eg, cluster headache and paroxysmal hemicrania). (See
         <a class="medical medical_review" href="/z/d/html/3326.html" rel="external">
          "Cluster headache: Epidemiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3334.html" rel="external">
          "Paroxysmal hemicrania: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
         Although mild migrainous features are occasionally present with the baseline continuous headache of HC, they are most often absent [
         <a href="#rid13">
          13
         </a>
         ]. However, migrainous features, such as photophobia and phonophobia, are commonly present during the headache exacerbations of HC [
         <a href="#rid6">
          6
         </a>
         ]. Less common clinical features that have been attributed to HC include a preceding aura, transition from episodic headaches (hemicrania episodica) to HC, side-alternating attacks, bilateral pain, and evolution from cluster headache [
         <a href="#rid7">
          7,14,15
         </a>
         ]. Whether these are truly features of HC as opposed to similar headache disorders is uncertain.
        </p>
        <p>
         Superimposed jabs and jolts (stabbing headache) occur frequently in patients with HC [
         <a href="#rid6">
          6
         </a>
         ]. Thus, some patients with HC also have primary stabbing headache and would be diagnosed with both headache types.
        </p>
        <p>
         Primary stabbing headache refers to brief, sharp, or jabbing pain in the head that occurs either as a single episode or in brief repeated volleys. The pain is usually over the ophthalmic trigeminal distribution, while the face is generally spared. The pain usually lasts a fraction of a second but can persist for up to one minute and recurs at irregular intervals (hours to days). The attacks commonly subside with the administration of
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/3327.html" rel="external">
          "Primary stabbing headache"
         </a>
         .)
        </p>
        <p>
         Absolute response to
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         therapy is required for the diagnosis of HC. This is discussed in greater detail below.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of HC is dependent upon the clinical features of the headache and the response to
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         . Diagnostic criteria (
         <a class="graphic graphic_table graphicRef62652" href="/z/d/graphic/62652.html" rel="external">
          table 1
         </a>
         ), according to the International Classification of Headache Disorders, 3
         <sup>
          rd
         </sup>
         edition (ICHD-3) are as follows [
         <a href="#rid16">
          16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (A) Unilateral headache
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (B) Present for more than three months, with exacerbations of moderate or greater intensity
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (C) Either or both of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (1) At least one of the following symptoms or signs, ipsilateral to the headache:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Conjunctival injection and/or lacrimation
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Nasal congestion and/or rhinorrhea
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Eyelid edema
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Forehead and facial sweating
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Miosis and/or ptosis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (2) A sense of restlessness or agitation or aggravation of the pain by movement
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (D) Responds absolutely to therapeutic doses of
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (E) Not better accounted for by another ICHD-3 diagnosis
        </p>
        <p>
        </p>
        <p>
         The ICHD-3 classification includes two subtypes of HC, a remitting form and an unremitting form [
         <a href="#rid16">
          16
         </a>
         ]. The remitting subtype of HC is characterized by pain that is not continuous but is interrupted by remission periods of at least 24 hours without treatment. The unremitting subtype of HC is characterized by continuous pain for at least one year without remission periods of at least 24 hours.
        </p>
        <p>
         Despite the definition of HC, some patients with the clinical phenotype of HC do not respond to
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         [
         <a href="#rid11">
          11,17
         </a>
         ]. A retrospective report from a tertiary headache center identified 165 patients seen from 1998 to 2007 with a putative diagnosis of HC who then had an adequate trial of indomethacin [
         <a href="#rid17">
          17
         </a>
         ]. An absolute response to indomethacin was observed in only 43 patients (26 percent). Furthermore, no predictors for indomethacin response were identified. This included the presence of autonomic symptoms, which were present in 57 percent of indomethacin-responsive and 61 percent of indomethacin-nonresponsive patients.
        </p>
        <p>
         The lack of predictors for
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         response led the investigators to suggest that all patients with continuous side-locked primary headaches receive an indomethacin trial (in the absence of contraindications to indomethacin) [
         <a href="#rid17">
          17
         </a>
         ]. However, the strength of this finding and recommendation is limited by the retrospective study design and sample size.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Diagnostic indomethacin trial
         </span>
         <span class="headingEndMark">
          —
         </span>
         As currently defined, the diagnosis of HC requires complete responsiveness to
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         [
         <a href="#rid16">
          16
         </a>
         ]. Either oral or parenteral indomethacin (where available) can be used to confirm the diagnosis of HC.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An oral
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         test can be used for the diagnosis of HC. Although there are variations in recommended titration schedules and doses, we start at 25 mg three times daily for three days, followed by 50 mg three times daily for three days, then 75 mg three times daily for three days as needed for headache resolution. Patients continue at the lowest effective dose. Completion of the test without headache resolution is considered a failed trial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Parenteral
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         given intramuscularly (the "indotest") has been used in clinical research as a standardized diagnostic test of HC [
         <a href="#rid18">
          18
         </a>
         ]. The indotest can also be applied in clinical practice for patient diagnosis. However, parenteral indomethacin for this purpose is
         <strong>
          not
         </strong>
         available in the United States. The test involves administration of intramuscular (IM) indomethacin (50 to 200 mg) to a patient who otherwise meets the clinical criteria for HC; the high end of this dose range comes from the ICHD-3 [
         <a href="#rid16">
          16
         </a>
         ]. In an open-label study of the indotest that included 12 patients with HC, administration of indomethacin 50 mg IM resulted in pain resolution after a mean interval from injection of 73 minutes [
         <a href="#rid18">
          18
         </a>
         ]. This beneficial effect endured for a mean of 13 hours [
         <a href="#rid18">
          18
         </a>
         ]. In four patients treated with indomethacin 100 mg IM, resolution of pain was noted after a mean of 61 minutes and the benefit endured for a mean of 13 hours. The indotest is also used for the diagnosis of paroxysmal hemicrania, another indomethacin-responsive primary headache disorder. (See
         <a class="medical medical_review" href="/z/d/html/3334.html" rel="external">
          "Paroxysmal hemicrania: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest performing a brain magnetic resonance imaging scan with contrast for all patients with suspected HC to exclude a structural brain lesion, particularly one involving the pituitary fossa. Even cases fitting all criteria for HC, including a complete response to
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         , can have a secondary etiology. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of primary HC (a strictly unilateral, continuous headache with superimposed exacerbations accompanied by autonomic features and migrainous symptoms) includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secondary hemicrania continua
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic migraine
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other trigeminal autonomic cephalalgias (TACs):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cluster headache
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The syndromes of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Paroxysmal hemicrania
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Secondary hemicrania continua
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are case reports of headaches mimicking primary HC (including response to
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         ) that are found to be secondary in nature [
         <a href="#rid19">
          19-24
         </a>
         ]. Associated etiologies have included internal carotid or vertebral artery dissection [
         <a href="#rid25">
          25,26
         </a>
         ], carotid cavernous fistula [
         <a href="#rid27">
          27
         </a>
         ], pineal cyst [
         <a href="#rid23">
          23
         </a>
         ], pituitary tumor [
         <a href="#rid28">
          28
         </a>
         ], ipsilateral mesenchymal tumor of the sphenoidal bone involving the clinoid process at the base of the skull [
         <a href="#rid20">
          20
         </a>
         ], lung adenocarcinoma [
         <a href="#rid29">
          29
         </a>
         ], pontine stroke [
         <a href="#rid21">
          21
         </a>
         ], nasopharyngeal carcinoma [
         <a href="#rid30">
          30
         </a>
         ], and inflammatory orbital pseudotumor [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Secondary HC should always be considered since secondary HC can be clinically indistinguishable from primary HC. However, secondary HC is more likely when any of the following conditions are present:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical picture is atypical.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are associated neurologic signs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The treatment response is poor.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Chronic migraine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic migraine, when strictly unilateral and side-locked, can be confused with HC. Autonomic features (eg, nasal congestion, rhinorrhea, lacrimation) can be associated with migraine headache, although they are typically less prominent than those seen with HC or other trigeminal autonomic cephalalgias. (See
         <a class="medical medical_review" href="/z/d/html/3337.html" rel="external">
          "Chronic migraine"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">
          "Pathophysiology, clinical manifestations, and diagnosis of migraine in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Other trigeminal autonomic cephalalgias
         </span>
         <span class="headingEndMark">
          —
         </span>
         The TACs are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features (eg, ptosis, miosis, lacrimation, conjunctival injection, rhinorrhea, and nasal congestion). Cluster headache, SUNCT and SUNA headache syndromes, and paroxysmal hemicrania are types of trigeminal autonomic cephalalgias that may occasionally be confused with HC (
         <a class="graphic graphic_table graphicRef65541" href="/z/d/graphic/65541.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cluster headache is characterized by attacks of severe unilateral orbital, supraorbital, or temporal pain accompanied by ipsilateral autonomic phenomena. Attacks usually last 15 to 180 minutes. In the episodic form, attacks occur daily, usually for weeks, followed by a period of remission. The chronic form of cluster headache lacks sustained remissions. (See
         <a class="medical medical_review" href="/z/d/html/3326.html" rel="external">
          "Cluster headache: Epidemiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SUNCT and SUNA are characterized by sudden brief attacks of severe unilateral head pain in orbital, periorbital, or temporal regions accompanied by ipsilateral cranial autonomic symptoms. The attack duration is 1 to 600 seconds, with at least 20 attacks per day. (See
         <a class="medical medical_review" href="/z/d/html/3336.html" rel="external">
          "Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Paroxysmal hemicrania is characterized by unilateral, brief, and severe attacks of pain associated with ipsilateral cranial autonomic features that recur several times per day. The headache is most often in the ophthalmic trigeminal distribution and lasts 2 to 30 minutes. The mean attack frequency is 11 to 14 daily. The syndrome is exquisitely responsive to
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/3334.html" rel="external">
          "Paroxysmal hemicrania: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Features that help to distinguish HC from the other TACs include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By definition, headache attacks are short lasting with SUNCT and SUNA (≤10 minutes) and paroxysmal hemicrania (≤30 minutes), and even cluster attacks are usually relatively short lived (≤180 minutes). In contrast, the pain in HC is continuous.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In general, the pain of HC is not as excruciatingly severe as the pain of other TACs.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          Indomethacin
         </a>
         is the treatment of choice for HC. Because the diagnosis of HC requires complete responsiveness to indomethacin, patients with HC typically continue taking the medication after their diagnostic trial. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Indomethacin regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with HC, the response to
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         is generally quite fast once reaching the appropriate dose, although the appropriate dose varies.
        </p>
        <p class="headingAnchor" id="H1204282549">
         <span class="h3">
          Maintenance dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial therapeutic dose is that which results in resolution of headache during the diagnostic
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         trial. (See
         <a class="local">
          'Diagnostic indomethacin trial'
         </a>
         above.)
        </p>
        <p>
         Sustained relief, which may be achieved at a lower maintenance dose, may help to minimize potential adverse effects [
         <a href="#rid16">
          16
         </a>
         ]. In a retrospective study, 16 adults with HC were started on
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         (25 mg every eight hours), and the dose was adjusted up or down as needed after two weeks [
         <a href="#rid32">
          32
         </a>
         ]. Complete symptomatic relief was achieved with a mean indomethacin dose of 78 mg (± 22 mg) daily. Seven patients were able to reduce the dose by a significant 56 percent, eight did not have any significant dose change, and one required a dose increase from 75 to 100 mg daily.
        </p>
        <p class="headingAnchor" id="H1378973332">
         <span class="h3">
          Weaning
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because sustained resolution during treatment may represent remission, patients should consider a trial of discontinuation of therapy [
         <a href="#rid33">
          33
         </a>
         ]. Trial of weaning after a six-month interval is reasonable [
         <a href="#rid32">
          32
         </a>
         ]. However, long-term treatment with
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         is often required due to recurrence of HC symptoms when doses of indomethacin are reduced.
        </p>
        <p>
         Relapse of symptoms may occur in some within days to weeks [
         <a href="#rid34">
          34
         </a>
         ]; patients may be able to resume prior effective maintenance dose. In a prospective study, 12 patients with HC discontinued
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         until headache recurred [
         <a href="#rid35">
          35
         </a>
         ]. Oral indomethacin was then restarted, based upon prior dose, at either 25 or 50 mg every eight hours until complete resolution of pain. The cumulative amount of indomethacin necessary to abort pain ranged from 25 to 150 mg. Complete pain relief was obtained within 8, 24, and 48 hours in 9, 10, and 12 patients, respectively.
        </p>
        <p class="headingAnchor" id="H3541759061">
         <span class="h3">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential side effects from
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         include the development of peptic ulcers, bleeding from platelet inhibition, exacerbation of anemia, hepatic dysfunction, renal dysfunction, exacerbation of hypertension, exacerbation of congestive heart failure, dizziness, and others. These issues are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">
          "Nonselective NSAIDs: Overview of adverse effects"
         </a>
         .)
        </p>
        <p>
         To minimize risk of gastrointestinal side effects, we suggest using the lowest effective maintenance dose. For patients with a history of peptic ulcer disease, we suggest using gastroprotection with proton pump inhibitors, H2-receptor antagonists, or (less often)
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         . Evidence to support this is discussed separately.
        </p>
        <p>
         As an alternative,
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         suppositories are occasionally helpful if gastric intolerance is a major problem or when high doses, such as 300 mg daily, are required. These issues are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/35.html" rel="external">
          "NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2658641500">
         <span class="h2">
          Alternative agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contraindications to treatment with
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         or discontinuation due to intolerance limits its usage in HC.
        </p>
        <p>
         There are case reports of improvement with several medications including cyclooxygenase-2 inhibitors,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         , melatonin,
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         ,
         <a class="drug drug_general" data-topicid="119169" href="/z/d/drug information/119169.html" rel="external">
          galcanezumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         [
         <a href="#rid36">
          36-41
         </a>
         ]. A 2017 review highlighted
         <a class="drug drug_general" data-topicid="9781" href="/z/d/drug information/9781.html" rel="external">
          piroxicam
         </a>
         and
         <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">
          celecoxib
         </a>
         as beneficial for acute treatment and additionally included topiramate and gabapentin for maintenance treatment [
         <a href="#rid42">
          42
         </a>
         ]. However, the actual benefit of each of these treatments should be considered unknown until larger studies are available.
        </p>
        <p>
         In addition, therapeutic benefit has been reported with several locally invasive neuromodulatory procedures:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          OnabotulinumtoxinA
         </a>
         [
         <a href="#rid43">
          43,44
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Greater occipital nerve blocks [
         <a href="#rid8">
          8
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Occipital nerve stimulation [
         <a href="#rid45">
          45
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sphenopalatine ganglion blocks or ablation [
         <a href="#rid46">
          46,47
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vagus nerve stimulation [
         <a href="#rid7">
          7,43,48-54
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         If multiple agents fail to provide substantial or sustained relief, reevaluation to consider secondary HC or another headache condition is warranted (see
         <a class="local">
          'Differential diagnosis'
         </a>
         above). Referral to a specialized center with expertise in treating these conditions, such as
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Famericanmigrainefoundation.org%2F&amp;token=j44%2B8gmRMaRaPv2EDaiVpQqjOaG0RmF7Dx2z2pSQDjCHdsLhntNWqYYG3TP9vC2Z&amp;TOPIC_ID=3342" target="_blank">
          The American Migraine Foundation
         </a>
         , can be considered.
        </p>
        <p class="headingAnchor" id="H645396473">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110285.html" rel="external">
          "Society guideline links: Migraine and other primary headache disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Hemicrania continua (HC) is a strictly unilateral, persistent headache with superimposed exacerbations of moderate to severe intensity that is typically associated with ipsilateral cranial autonomic symptoms, a sense of restlessness or agitation during exacerbations, and responsiveness to
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         . (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of HC is dependent upon the clinical features of the headache and the response to
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         (
         <a class="graphic graphic_table graphicRef62652" href="/z/d/graphic/62652.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Either oral or parenteral
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         (where available) can be used to confirm the diagnosis of HC. (See
         <a class="local">
          'Diagnostic indomethacin trial'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with suspected HC, we suggest performing a brain magnetic resonance imaging scan to exclude a structural brain lesion. (See
         <a class="local">
          'Neuroimaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of primary HC includes secondary HC, chronic migraine, cluster headache, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) headache syndromes, and paroxysmal hemicrania (
         <a class="graphic graphic_table graphicRef65541" href="/z/d/graphic/65541.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         –
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          Indomethacin
         </a>
         is the treatment of choice for HC, which is defined by its responsiveness to this drug. Gastroprotection with proton pump inhibitors reduces the risk of gastrointestinal side effects. When indomethacin treatment is not tolerated, trials of alternative agents are reasonable. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Matharu MS, Cohen AS, McGonigle DJ, et al. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache 2004; 44:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goadsby PJ, Matharu MS, Boes CJ. SUNCT syndrome or trigeminal neuralgia with lacrimation. Cephalalgia 2001; 21:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sjaastad O, Spierings EL. "Hemicrania continua": another headache absolutely responsive to indomethacin. Cephalalgia 1984; 4:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prakash S, Patel P. Hemicrania continua: clinical review, diagnosis and management. J Pain Res 2017; 10:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Khazali HM, Al-Khazali S, Iljazi A, et al. Prevalence and clinical features of hemicrania continua in clinic-based studies: A systematic review and meta-analysis. Cephalalgia 2023; 43:3331024221131343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peres MF, Silberstein SD, Nahmias S, et al. Hemicrania continua is not that rare. Neurology 2001; 57:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dodick D. Hemicrania continua: diagnostic criteria and nosologic status. Cephalalgia 2001; 21:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain 2010; 133:1973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bordini C, Antonaci F, Stovner LJ, et al. "Hemicrania continua": a clinical review. Headache 1991; 31:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalgias and hemicrania continua. Drugs 2003; 63:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prakash S, Golwala P. A proposal for revision of hemicrania continua diagnostic criteria based on critical analysis of 62 patients. Cephalalgia 2012; 32:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman LC, Lipton RB, Solomon S. Hemicrania continua: ten new cases and a review of the literature. Neurology 1994; 44:2111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bigal ME, Tepper SJ, Rapoport AM, Sheftell FD. Hemicrania continua: comparison between two different classification systems. Cephalalgia 2002; 22:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peres MF, Siow HC, Rozen TD. Hemicrania continua with aura. Cephalalgia 2002; 22:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matharu MS, Bradbury P, Swash M. Hemicrania continua: side alternation and response to topiramate. Cephalalgia 2006; 26:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marmura MJ, Silberstein SD, Gupta M. Hemicrania continua: who responds to indomethacin? Cephalalgia 2009; 29:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the 'indotest'. Headache 1998; 38:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eross EJ, Swanson JW, Dodick DW. Hemicrania continua: an indomethacin-responsive case with an underlying malignant etiology. Headache 2002; 42:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonaci F, Sjaastad O. Hemicrania continua: a possible symptomatic case, due to mesenchymal tumor. Funct Neurol 1992; 7:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valença MM, Andrade-Valença LP, da Silva WF, Dodick DW. Hemicrania continua secondary to an ipsilateral brainstem lesion. Headache 2007; 47:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogalewski A, Evers S. Symptomatic hemicrania continua after internal carotid artery dissection. Headache 2005; 45:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peres MF, Zukerman E, Porto PP, Brandt RA. Headaches and pineal cyst: a (more than) coincidental relationship? Headache 2004; 44:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy MJ, Matharu MS, Meeran K, et al. The clinical characteristics of headache in patients with pituitary tumours. Brain 2005; 128:1921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabata H, Kitaguchi H. Hemicrania Continua Subsequent to Vertebral Artery Dissection: A Case Report. J Stroke Cerebrovasc Dis 2019; 28:104443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brilla R, Pawlowski M, Evers S. Hemicrania continua in carotid artery dissection - symptomatic cases or linked pathophysiology? Cephalalgia 2018; 38:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold Fiebelkorn C, Lanzino G, Chen JJ, et al. Carotid Cavernous Fistula Mimicking Hemicrania Continua: A Case Report. Headache 2019; 59:1365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan TLH. Hemicrania continua secondary to pituitary macroadenoma responsive to nerve blocks: A case report. Headache 2021; 61:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robbins MS, Grosberg BM. Hemicrania continua-like headache from metastatic lung cancer. Headache 2010; 50:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Wang D, He Z, et al. Hemicrania continua-like headache secondary to nasopharyngeal carcinoma: A case report. Cephalalgia 2017; 37:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeLange JM, Robertson CE, Krecke KN, Garza I. A case report of hemicrania continua-like headache due to ipsilateral inflammatory orbital pseudotumor. Headache 2014; 54:1541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pareja JA, Caminero AB, Franco E, et al. Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua. Cephalalgia 2001; 21:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prakash S, Rawat KS. A case of remitting hemicrania continua with seasonal variation and clustering: a diagnostic confusion with cluster headache. BMJ Case Rep 2019; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen AS, Matharu MS, Goadsby PJ. Trigeminal autonomic cephalalgias: current and future treatments. Headache 2007; 47:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pareja J, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Interval between indomethacin administration and response. Headache 1996; 36:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González-Quintanilla V, Pérez-Pereda S, Fontanillas N, Pascual J. First case of hemicrania continua responsive to galcanezumab. Neurol Sci 2021; 42:4775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller KI, Bekkelund SI. Hemicrania continua changed to chronic paroxysmal hemicrania after treatment with cyclooxygenase-2 inhibitor. Headache 2011; 51:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mariano Da Silva H, Alcantara MC, Bordini CA, Speciali JG. Strictly unilateral headache reminiscent of hemicrania continua resistant to indomethacin but responsive to gabapentin. Cephalalgia 2002; 22:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollingworth M, Young TM. Melatonin responsive hemicrania continua in which indomethacin was associated with contralateral headache. Headache 2014; 54:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prakash S, Rana K. Topiramate as an Indomethacin-Sparing Agent in Hemicrania Continua: A Report of 2 Cases. Headache 2019; 59:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajabally YA, Jacob S. Hemicrania continua responsive to verapamil. Headache 2005; 45:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baraldi C, Pellesi L, Guerzoni S, et al. Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. J Headache Pain 2017; 18:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller S, Correia F, Lagrata S, Matharu MS. OnabotulinumtoxinA for hemicrania continua: open label experience in 9 patients. J Headache Pain 2015; 16:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalil M, Ahmed F. Hemicrania continua responsive to botulinum toxin type a: a case report. Headache 2013; 53:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller S, Watkins L, Matharu MS. Treatment of intractable hemicrania continua by occipital nerve stimulation. J Neurol Neurosurg Psychiatry 2017; 88:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Androulakis XM, Krebs KA, Ashkenazi A. Hemicrania continua may respond to repetitive sphenopalatine ganglion block: A case report. Headache 2016; 56:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans RW. Radiofrequency Ablation of the Sphenopalatine Ganglion for Hemicrania Continua: The Second Case Report of a Long-Term Pain-Free Response. Headache 2020; 60:1438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peres MF, Silberstein SD. Hemicrania continua responds to cyclooxygenase-2 inhibitors. Headache 2002; 42:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rozen TD. Verapamil-responsive hemicrania continua in a patient with episodic cluster headache. Cephalalgia 2006; 26:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spears RC. Hemicrania continua: a case in which a patient experienced complete relief on melatonin. Headache 2006; 46:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rozen TD. Melatonin responsive hemicrania continua. Headache 2006; 46:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwedt TJ, Dodick DW, Hentz J, et al. Occipital nerve stimulation for chronic headache--long-term safety and efficacy. Cephalalgia 2007; 27:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garza I, Cutrer FM. Pain relief and persistence of dysautonomic features in a patient with hemicrania continua responsive to botulinum toxin type A. Cephalalgia 2010; 30:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tso AR, Marin J, Goadsby PJ. Noninvasive Vagus Nerve Stimulation for Treatment of Indomethacin-Sensitive Headaches. JAMA Neurol 2017; 74:1266.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3342 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15330820" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Posterior hypothalamic and brainstem activation in hemicrania continua.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11422087" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : SUNCT syndrome or trigeminal neuralgia with lacrimation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6713526" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : "Hemicrania continua": another headache absolutely responsive to indomethacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28721092" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hemicrania continua: clinical review, diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36588185" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prevalence and clinical features of hemicrania continua in clinic-based studies: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11577748" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hemicrania continua is not that rare.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11903278" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hemicrania continua: diagnostic criteria and nosologic status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20558416" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Hemicrania continua: a clinical study of 39 patients with diagnostic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2016164" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : "Hemicrania continua": a clinical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12904085" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Management of trigeminal autonomic cephalgias and hemicrania continua.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22751966" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A proposal for revision of hemicrania continua diagnostic criteria based on critical analysis of 62 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7969968" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hemicrania continua: ten new cases and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12047465" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hemicrania continua: comparison between two different classification systems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12047466" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hemicrania continua with aura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16472344" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hemicrania continua: side alternation and response to topiramate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19220311" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Hemicrania continua: who responds to indomethacin?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9529768" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the 'indotest'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12167144" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Hemicrania continua: an indomethacin-responsive case with an underlying malignant etiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1297626" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hemicrania continua: a possible symptomatic case, due to mesenchymal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17371363" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Hemicrania continua secondary to an ipsilateral brainstem lesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15705126" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Symptomatic hemicrania continua after internal carotid artery dissection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15447706" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Headaches and pineal cyst: a (more than) coincidental relationship?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15888539" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The clinical characteristics of headache in patients with pituitary tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31611169" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Hemicrania Continua Subsequent to Vertebral Artery Dissection: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28056533" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hemicrania continua in carotid artery dissection - symptomatic cases or linked pathophysiology?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31166017" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Carotid Cavernous Fistula Mimicking Hemicrania Continua: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34105160" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hemicrania continua secondary to pituitary macroadenoma responsive to nerve blocks: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20618818" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hemicrania continua-like headache from metastatic lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27288353" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Hemicrania continua-like headache secondary to nasopharyngeal carcinoma: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25168202" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A case report of hemicrania continua-like headache due to ipsilateral inflammatory orbital pseudotumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11903285" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31110069" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A case of remitting hemicrania continua with seasonal variation and clustering: a diagnostic confusion with cluster headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17578559" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Trigeminal autonomic cephalalgias: current and future treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8666531" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Chronic paroxysmal hemicrania and hemicrania continua. Interval between indomethacin administration and response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34287725" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : First case of hemicrania continua responsive to galcanezumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21284612" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Hemicrania continua changed to chronic paroxysmal hemicrania after treatment with cyclooxygenase-2 inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12110117" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Strictly unilateral headache reminiscent of hemicrania continua resistant to indomethacin but responsive to gabapentin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24261314" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Melatonin responsive hemicrania continua in which indomethacin was associated with contralateral headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30802948" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Topiramate as an Indomethacin-Sparing Agent in Hemicrania Continua: A Report of 2 Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16109126" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Hemicrania continua responsive to verapamil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28730562" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25902798" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : OnabotulinumtoxinA for hemicrania continua: open label experience in 9 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23534367" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Hemicrania continua responsive to botulinum toxin type a: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28255029" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Treatment of intractable hemicrania continua by occipital nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26926875" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Hemicrania continua may respond to repetitive sphenopalatine ganglion block: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33314102" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Radiofrequency Ablation of the Sphenopalatine Ganglion for Hemicrania Continua: The Second Case Report of a Long-Term Pain-Free Response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12167145" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Hemicrania continua responds to cyclooxygenase-2 inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16472347" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Verapamil-responsive hemicrania continua in a patient with episodic cluster headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16618278" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Hemicrania continua: a case in which a patient experienced complete relief on melatonin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16866728" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Melatonin responsive hemicrania continua.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17257236" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Occipital nerve stimulation for chronic headache--long-term safety and efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19515122" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Pain relief and persistence of dysautonomic features in a patient with hemicrania continua responsive to botulinum toxin type A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28846758" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Noninvasive Vagus Nerve Stimulation for Treatment of Indomethacin-Sensitive Headaches.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
